AQR Capital Management
MRNS

AQR Capital Management’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

AQR Capital Management’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-31,333
Closed -$36.7K – 2918
2024
Q2 		$36.7K Buy
31,333
+12,934
+70% +$32.4K ﹤0.01% 2553
2024
Q1 		$166K Sell
18,399
-4,625
-20% -$45K ﹤0.01% 2283
2023
Q4 		$250K Buy
+23,024
New +$173K ﹤0.01% 2134
2021
Q2 		– Sell
-11,535
Closed -$179K – 2315
2021
Q1 		$179K Sell
11,535
-3,901
-25% -$56.4K ﹤0.01% 2125
2020
Q4 		$188K Buy
+15,436
New +$215K ﹤0.01% 2097
2019
Q2 		– Sell
-4,712
Closed -$79K – 2210
2019
Q1 		$79K Buy
+4,712
New +$67.8K ﹤0.01% 2145
2018
Q4 		– Sell
-17,429
Closed -$697K – 2301
2018
Q3 		$697K Hold
17,429
– – ﹤0.01% 1837
2018
Q2 		$493K Buy
+17,429
New +$386K ﹤0.01% 1984

Other funds holding MRNS

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

AQR Capital Management's MRNS Position: Q3 2024 in Review

AQR Capital Management sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q3 2024, closing a stake of 31,333 shares — an estimated $36.7K sold.

AQR Capital Management first reported a position in MRNS in Q2 2018 and held it in 8 quarters. The position peaked at $697K in Q3 2018. 75 funds tracked by Wall St. Rank hold MRNS as of Q3 2024.

  • AQR Capital Management reported no remaining Marinus Pharmaceuticals, Inc position as of Q3 2024 after selling out during the quarter.
  • AQR Capital Management sold 31,333 Marinus Pharmaceuticals, Inc shares in Q3 2024, an estimated $36.7K.
  • AQR Capital Management first reported a position in Marinus Pharmaceuticals, Inc in Q2 2018 and held it in 8 quarters.
  • AQR Capital Management's Marinus Pharmaceuticals, Inc position peaked at $697K in Q3 2018.
  • 75 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q3 2024.

Based on AQR Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.